Categories October Surprise 2024 FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2 … Post author By Post date January 2, 2025 Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HERā) gastric or gastroesophageal junction …